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ABSTRACT 
Segmentation in the pharmaceutical industry is blurred by the complicated market dynamics of the 
industry: even the classic definition of the customer is not relevant. The customer base is made up of 
a number of stakeholders which includes the patient and caregiver. These patients and caregivers have 
become more empowered and are using the internet as their primary source of information. The 
internet is developing at an astonishing rate and even healthcare professionals have embraced it. 
Legislative restrictions make it difficult for marketers to communicate directly with patients, so new 
strategies need to be developed. This paper looks at the impact of online media on market 
segmentation within the pharmaceutical industry. It provides practical solutions on how to tackle the 
dilemma. 
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Introduction. 
 
The impact of online media has and will continue to generate a great deal of interest across many 
businesses, yet most pharmaceutical companies struggle with the concept.1 Patients and caregivers 
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have become more active in their pursuit for health information. 2 Studies have shown that over 85% 
now use the internet as their primary source of data. 3 The website “PatientsLikeMe” is an example 
of how individuals with life changing illnesses share their experiences with others. It reports to have 
over 72,000 members in its community. Their primary goal is to give patients an insight to their 
future, highlighting the prognosis and likely quality of life expectancies. 4 
 
It is not just the patients and their caregivers who are using these online portals for first-hand 
information. A study by Google5 identified 86% of physicians use the internet for medical research: 
more importantly, 77% focus specifically on drug data and 31% have changed a patient’s medication 
following the review. The study also identified that the majority use search engines to find material: 
drilling into the top three results only. This means that pharmaceutical companies have to optimise 
and update their websites with the appropriate keywords if they hope to utilise online media as a 
source to generate new business. 
 
The growth of medical websites has been phenomenal although it is difficult to substantiate the 
statement.  In an attempt to validate it, this paper carried out a simple exercise looking at some basic 
medical search terms using Google in January 2011. The objective was to identify how many likely 
pages were available for the users to review. The results are illustrated in table 1: 
 
Search Term Approximate results 
Medical symptoms 15,200,000 
Medical Advice 28,600,000 
Medical Therapies 8,230,000 
Table 1: Google search results count. 
 
The exercise also looked at users’ online search habits: it identified that there were just over 45 million 
monthly searches for the terms related to medical symptoms, advice and therapies (this study was 
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done using Google’s keyword analyser). Based on the current internet evolution statistics, one can 
conclude that it is only likely to grow. Online media cannot and should not be ignored by 
pharmaceutical companies. Unfortunately, very few pharmaceutical company websites appear on 
page one of Google when users search for terms relating to medical symptoms, advice or therapies.  
 
Figures for 2008 indicate that there were over 1.5 billion internet users6 which is roughly 26% of the 
world population. The 10 year growth of internet users was over 750%.6 It is not just computers 
driving the expansion; the sales of smartphones, which also provides a channel to access online media, 
grew by 96% in the 3rd quarter last year.7 They now occupy just under 20% of the mobile phone 
market. 
 
Online media has removed geographical barriers; it can create numerous opportunities for a medical 
marketing team to increase its brand awareness across the world. These brands will provide 
pharmaceutical companies with the opportunity to connect with its customers;8,9 both healthcare 
professionals and patients. Brand management should not be limited to just the product portfolio, they 
must include all services and the corporate image. There is a concern however, Giles10 identified that 
marketers within the industry have a poor understanding of the concept of branding. Businesses need 
to re-evaluate their marketing structure and look to the internet as a means of obtaining new 
opportunities.  
 
Before embarking on such a venture, pharmaceutical companies must first decide exactly who its 
customers are and how it deals with them. Patients and caregiver are the ultimate consumers but 
regulatory restrictions make it difficult for direct communications.11 Is this likely to change? Should 
this situation be challenged? 
 
Pharmaceutical Companies’ Customers. 
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When it comes to prescription only medicines (POMs), most people think that pharmaceutical 
companies deal directly with healthcare professionals (HCPs):  physicians, pharmacists, nurses etc. 
They in turn manage the patients and caregivers (see figure 1): 
 
Figure 1: Old interaction between pharmaceutical companies, HCPs and patients. 
 
This belief is largely due to the legislative constratints that drive the industry’s code of practice. As 
it has already been mentioned, the advent of social media has meant that patients and caregivers have 
become more empowered and are demanding more from the sector. It means that pharmaceutical 
companies need to move to an integrated communications model (see figure 2): 
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Figure 2: New interaction between pharmaceutical companies, HCPs and patients. 
 
In doing so, they must not alienate HCPs or infringe regulatory protocol. Regrettably the model 
painted above does not give the full picture. In reality pharmaceutical companies have a much more 
complicated customer base. The classic definition of a customer is: 
 
A person who buys goods or services from a shop or business. 
Oxford English Dictionary12 
 
Such a definition does not serve the pharmaceutical market and this paper would like to propose 
changing the definition to: 
 
Customers of pharmaceutical companies are made up of a series of stakeholders. Each group 
of stakeholders provide access or authority to the next level of stakeholders to either; list, buy, 
prescribe, use or consume the products (or services). 
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In essence, the market is very different to that of the normal B2B or B2C industries. Here the market 
is made up of stakeholders who act as gatekeepers, guarding the access to the next stage. A product 
has to go through a number of gatekeepers before it can be finally consumed or used. These 
gatekeepers have very specific requirements that need satisfying before the business can move to the 
next level. The process is made more complicated by the fact that different counties have very 
different rules and regulations relating to how a product can be introduced. Figure 3 illustrates the 
flow of the customer chain with examples of who the stakeholders are: 
 
Figure 3 : A typical pharmaceutical company’s customer chain. 
 
The author has learnt from experience that many pharmaceutical companies have already segmented 
the first three sets of stakeholders. Each tends to be managed by separate teams but little consideration 
is made to the variability within these segments. More alarmingly, the fourth stakeholder group of 
consumers is seldom considered at all. Yet it potentially provides one of the biggest opportunities for 
the business. Clearly the question of segmentation strategies should be considered as part of the 
executive agenda.  
 
Segmentation Strategies. 
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Segmentation is essentially a classification exercise, where individuals are believed to be related in 
certain ways.13 It allows organisations to develop strategies which maximise their product’s 
potential.14 When developing such strategies, businesses should see the market being composed of 
many different divisions.15 Marketers should design their products and services to target specific 
segments and although Dibb16 argues that there are many different interpretations of this theory, the 
underlying principle is that it targets a selection of customers in order to provide a specific 
promotional message. 
 
Kotler17 suggests that segmentation, targeting and positioning are all interlinked: segmentation 
centres on the variables within a market; targeting is about deciding how many segments should be 
targeted; positioning places the products or services in the mind of the customer by communicating 
the desired benefit. Kotler also suggested that a business could either: 
 
• Concentrate on a single segment with one product and marketing mix. 
• Offer one product and marketing mix to a number of different segments. 
• Produce different products and marketing mixes for each segment. 
 
Unfortunately these ideas are not wholly true for the medical sector. This paper has already 
highlighted the fact that the classic definitions of a market and its customers are not relevant: there 
are many stakeholders that need satisfying before the market can be unlocked.  As such, the 
segmentation model which was first developed by Smith18 needs to be adapted specifically for 
pharmaceutical companies.  
 
A review of the customer chain has identified that the number of stakeholders increases substantially 
as it gets closer to the final consumer (see figure 4). This means that a single approach to segmentation 
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across the whole chain is likely to lead to the wrong conclusions. This paper proposes that the 
segmentation exercise should be done in two stages: 
 
1. The first stage focuses on the market access phase. (ie, the regulatory bodies, strategic buying 
authorities and insurance companies). 
2. The second stage focuses on market development. (ie, the healthcare professionals, patients 
and caregivers). 
 
 
Figure 4 : Number of individuals involved in the customer chain. 
 
Stage One: Market Access  
The first stage is all about filling a need: it identifies the commercial viability for launching a new 
product or creating a new service. The stakeholders involved require a holistic view of the product 
and its proposed use. The numbers involved in this group are small, which means that the marketing 
and sales process can be tailored to suit each individual’s need. These individual plans tend to focus 
on: 
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• Therapy. 
• Geographic. 
• Demographic. 
• Psychographic. 
• Behaviouristic. 
 
The concept is best demonstrated with an example (note, this example is purely illustrative): 
 
A pharmaceutical company is looking to launch a new drug in England. The drug is to be 
taken orally once a day to treat paediatric epilepsy. 
 
Therapy is an oral anti-epileptic drug. 
 
Geography is England, so the target stakeholders will be the National Institute for Health and 
Clinical Excellence (NICE) and then the 10 strategic health authorities located in England 
(once approval has been given by NICE). 
 
Demographics apply to children with epilepsy, so an analysis of the prevalence of this 
condition is required to support the business case. 
 
Psychographics is based on the fact that neurologist and parents prefer administering an oral 
treatment as opposed to any evasive surgery (note, there are no studies to back this point, it is 
only being used as an illustration). 
 
Behaviouristic relates to the health economics of the product and how it can benefit the 
quality of life for the patient. 
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So, even though the plans were developed to suit individual needs there are clearly elements of the 
classic segmentation process included in the final analysis.  The marketing or commercial teams 
involved need to understand the importance of this factor. 
 
Stage Two: Market Development 
The second stage relates to the market development phase. Here, the stakeholders will either; 
prescribe, use, administer or consume the products. These individuals will be the HCPs, patients or 
caregivers and the numbers involved could now be in the millions. This means that the expectations 
and needs are likely to vary significantly. A single marketing message will not satisfy the total market 
requirement: further segmentation must take place with the appropriate marketing strategies 
incorporated. Unfortunately, it has been the author’s experience that too many businesses still focus 
on developing a single message for the HCP group.  This hypothesis is reinforced by Jenkins and 
McDonald19 who identified that managers tend to segment their markets not on customer groupings 
but on internal products.  
 
Segmentation is a skill and should be classed as a science, backed up with evidence. This means that 
marketers will have to master a new range of technical competences. For those who are already 
embracing it, there should be no issues. For those who have not, they face a painful journey along the 
path of change.20 Indeed, Levitt21 had already identified that there are many businesses that are 
unwilling to recognise change for fear that it will undermine their entire strategy. Levitt’s21 study 
focused on the general business environment, so does his theory replicate itself when considering 
pharmaceutical companies? The question goes beyond the brief of this paper, but further research 
would be interesting. Needless to say, for success to be achieved, the issues related to change 
management must be addressed. 
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Today’s economic climate brings with it many caveats, least of which are the pressures on time and 
resource. To date, there is no agreement on any formal way of carrying out segmentation: it is highly 
unlike that such a generic procedure would work for this sector anyway. In fact, there have been many 
academics who have argued against adopting a formal segmentation processes,22 but equally, there 
have been even more who advocate the use of complex systems.23 
 
Clearly some form of segmentation must take place. The solution must be simple and effective if it 
is to be adopted by practitioners. Cluster analysis could be the answer: many market researches 
already used it as a means of classification.13 It is an inductive technique and the empirical rules it 
uses can easily be amended and developed to suit any needs. 
 
The technique proposed is an adapted version of divisive clustering.24 It is one that the author has 
already employed with great success. All customers are initially treated as a single large cluster, they 
are then divided into smaller and smaller clusters. The premise is centered on the buying (or usage) 
behaviours because such a factor is easily obtained by companies. The method is as follows (see also 
table 2 for an example): 
 
1. Focus on HCPs data only (it is generally much easier to obtain). 
2. Obtain the sales (usage) figures by customers for a given period (annual figures would be 
best). 
3. Sort the data into descending order, then for each customer calculate the cumulative sales. 
4. Establish the percentage that each cumulative value is of the total sales. 
5. Split the data into three clusters (this is the process of dividing into smaller groups): 
 
• Percentage of cumulative sales less than or equal to 25%. 
• Percentage of cumulative sales greater 25% but less than or equal to75%. 
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• Percentage of cumulative sales greater 75%. 
 
 
Table 2: An example of the clustering method. 
 
Four distinct clusters are created (the principles are similar to that used in the Pareto analysis25) which 
the author has called: 
 
• Advocates. 
• Users. 
• Testers. 
• Newbies: this group is not in the sales (usage) figures as they are potential customers who are 
not currently buying or using the product yet. 
 
Advocates are the top prescribers, the number of stakeholders involved in this group is small, 
which means that the marketing and sales process can be tailored to suit the individual’s need. 
They will account for approximately 1% to 5% of the customer base. These HCPs are ideal 
candidates to help promote the product amongst their peers. 
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Users account for the bulk of the business: their numbers range from between 10% to 15% of the 
customer base. The plan should be to convert users into advocates. 
  
Testers account for approximately 75% of the customer base. This segment tends to be the long 
tail of the portfolio and it provides the business with the greatest opportunity for gaining extra 
market share. 
 
Newbies are those individuals not doing any business with the organisation, hence they do not 
appear on the sales list. They may be unaware of the product(s) or service(s) provided by the 
pharmaceutical company or have chosen to ignore them.  The business needs to introduce 
strategies to entice these individuals to use the brands.  
 
Due to privacy laws, the information relating to patients and their product usage will be difficult to 
obtain. Expensive market research programmes are needed to establish the clusters. The author has 
been fortunate enough to have carried out a number of these reviews covering different disease 
groups. In all, it can be concluded that the profiles are very similar to that identified in the HCP group.  
The advocates tend to be the chronic sufferers. The users are those with the classic symptoms who 
comply well with their medical regimen. The testers tend to be those individuals who have either 
classic or mild symptoms but have poor compliance. Finally the newbies are a mixture of the chronic, 
classical and mild suffers but are all on different medications (if at all any). 
 
Having identified all these different groups of customers what should a business now be doing? Each 
cluster has very different needs so tactical plans must be developed to satisfy them. The best way to 
do that is to review the marketing mix. 
 
Segmentation and the Marketing Mix. 
 
 
14 A Shaw 
It can be argued that the marketing mix acts as the foundation for setting all marketing plans. Many 
businesses focus solely on the four Ps: Price, Promotion, Place and Product. It was Borden26 who 
expanded the concept to include; Process, Physical Evidence and People. On further inspection it has 
become clear that this extended mix is more relevant for pharmaceutical companies than any others. 
It is this mix that needs to be considered when trying to manage the various segments identified above.  
 
The best way to analyse the factors is to consider each of the marketing mix elements individually 
whilst comparing it to the various segments: 
 
Product: The product familiarisation is critical when dealing with the HCPs. Sampling and 
demonstrations are the best way to increase awareness. Online media is also a good way of 
spreading the word and there are a number of tactical strategies that can be put in place 
including email marketing, webinars (web seminars), video and audio podcasts. Due to 
legislative restrictions, pharmaceutical companies cannot target patients and caregivers 
directly with product information (POM products). They have to use utilise the concept of 
medical education and promote the corporate brand instead. 
  
Promotion: PR, advertising and promotion is all about generating the right message; it should 
focus on the customer’s needs.  An element of research is required for this process. Sinha28 
supports the idea that businesses should utilise the key rule of “pull marketing”: allowing the 
customer to discover the product or service themselves instead of having it constantly pushed 
in front of them. With over 45 million searches done every month on words and phrases 
related to medical symptoms, the internet must be the ideal place to focus the promotion plan.  
Bearing in mind that the “testers” and “Newbies” account for over 80% of the market, could 
such a tactic generate more business? No studies are available for the pharmaceutical sector 
but there is a lot of evidence to support in the wider commercial field. 27 
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Once again the rules of marketing need to change, as this paper has already mentioned, 
legislation restricts manufacturers advertising directly to patients and caregivers. Many 
pharmaceutical companies still adopt the safe route and focus only on HCPs. Regrettably, if 
businesses want to dominate the results of internet searches, they need to mobilise the bulk of 
the users: these happen to be the patients and caregivers. E-strategies need to be developed 
with external link building programmes27 and it is the patients and caregivers who they should 
target. To avoid falling foul of the regulations, businesses should focus on medical education 
as a means to capture the imagination of these consumers: if they like it they will share it in 
the electronic community. In turn it will increase the equity of the web page and move it up 
the Google ranking (be warned this is not an overnight fix). 
  
Price: The product price will depend on the sector and geographical region. As an example, 
patients in the USA are more sensitive to price than patients in the UK. This is due to the fact 
that US citizens have to pay indirectly through their health insurance systems whereas UK 
citizens will have it reimbursed through the National Health system. Price is also often used 
as a tool to entice new customers or maintain the business: this could mean that the marketing 
mix is out of sync and the brand equity is being eroded. 
 
Place / distribution: There are a number of channels open to pharmaceutical companies and 
they include: 
 
• Hospital channels. 
• Community channels 
• Pharmacy Channels. 
• Home Delivery channels. 
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• Internet channels. 
 
With the exception of the first stakeholder group (regulator bodies), all the other segments are 
likely to be interested in this characteristic. In reality it creates additional sub-segments and 
sub-clusters. The skilled marketer should see this as an opportunity to add value. 
 
Process: These are the systems used by the pharmaceutical company to support the 
management and delivery of the products and services. More and more of the stakeholders 
are demanding a better flow of information. There are now extranets that provide secure 
details about pricing, rebates, deliveries and much more. This element can be a real 
differentiator: it could be a reason why a company could lose or gain business.  
 
The process will impact all segments and clusters: the easier it is the more likely customers 
will stay and do business. 
 
Physical evidence: In the medical industry, physical evidence is paramount. It is the first and 
third group of stakeholders (regulatory bodies and HCPs) that focus on this factor, although 
as already mentioned, patients and caregivers have begun to review product efficacy. HCPs 
rely on detail documentation of clinical trials but the consumers look to forums and social 
networks for their information. Marketers need to start reviewing how their brands are being 
perceived over the internet.  
 
Advocates and users are likely to be less concerned about the physical evidence whereas 
testers and newbies will need more reassurance. 
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People: The people aspect is critical in the selling process. The second and third stakeholder 
groups (strategic buying authorities and HCPs) are where pharmaceutical companies should 
concentrate their efforts. Relationship building in medical sales can be the factor that wins the 
order.29 The link to the patient and caregiver is very much at an “arms distance”: the use of 
traditional and electronic communications tools are the mechanisms used to include this 
segment. 
 
Advocates and users require careful management: customer retention must remain a top 
priority for any business. The sales team will need to work on building the relationship in the 
tester and newbie segments: a focus on trust and support is key to building the business. 
 
It should be very clear to the reader that segmentation within the medical sector is very different to 
that of the general industry. To be successful pharmaceutical companies must adapt and apply their 
strategic and tactical plans to each group. They must also start to consider how to incorporate the 
internet into these plans. 
 
 
Conclusion and Further Research. 
Segmentation is all about positioning brands and targeting customers using a various marketing 
mixes. Promotion is a key element of the marketing mix and the internet is the ideal means for 
disseminating specific messages. Patients and caregivers play an important part in optimising search 
engine results because of the numbers involved. Pharmaceutical marketers need to start including 
medical education strategies on the web when promoting their brands because online media has 
already had a major impact in sectors outside of the medical industry. It is highly likely that success 
will be seen by those medical companies that embracing this channel. 
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The segmentation process reviewed was based on products that had already been developed. It looked 
at the interaction between the customers providing the licence for use, those that listed it on their 
buying portfolios, those that prescribed it and finally those that ultimately consumed it.  No attempt 
was made to look at segmentation “pre-product development”. Would there be any different processes 
or types of segmentation? The author suggests that it is highly likely and that companies would have 
different means to manage the area. Some could be classed as “market orientated organizations”,30  
involving customers at every stage. The others would be those who were “product orientated 
organization”31 where R&D make all the decisions. Either way, it is unclear what part marketing 
would play in the process and how the markets would be segmented. Further research should be 
carried out to look at this particular dilemma. 
 
The paper identified that the segmentation process was a means for businesses to position and target 
their brands with different marketing mixes. It also identified that the internet has a big part to play 
in getting the message to the patients and their caregivers. These messages should be restricted to 
medical education. Direct referencing of products is not allowed so it is the corporate brand that is 
promoted. It is not clear how pharmaceutical companies organised themselves to share the 
responsibilities of brand management of products and the corporate image. It is highly likely that 
companies have not even considered it yet. Further research should be carried out to look at how 
brand managers integrate the corporate image into their daily routines. 
 
References were made specifically to pharmaceutical companies and the products considered were 
classed as POMs. The author would argue that there are many similarities to those companies 
producing medical devices, nutriceuticals (foods for special medical purposes), veterinary, dental and 
even cosmetic surgery. There are also synergies with over the counter (OTC) products. As such, the 
concept of segmentation described above can easily be adapted to cover these sectors. 
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Finally, the process of segmentation is confusing; it is compounded by the complicated market 
dynamics of the medical industry. There are a number of bodies (including the Chartered Institute of 
Marketing and the American Marketing Association) that could produce clear guidelines on how the 
industry should organise itself. 
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